阿托伐他汀钙片联合丁苯酞软胶囊治疗脑梗死患者的临床效果及安全性分析  

Clinical effect and safety analysis of atorvastatin calcium tablets combined with butylphthalein soft capsules in the treatment of cerebral infarction patients

作　　者：韦玲云 敖潇 韦慧 韦园梅 WEI Ling-yun;AO Xiao;WEI Hui(Hechi People's Hospital,Hechi 547000,China)

机构地区：[1]河池市人民医院,547000

出　　处：《中国现代药物应用》2023年第23期119-122,共4页Chinese Journal of Modern Drug Application

摘　　要：目的评估阿托伐他汀钙片联合丁苯酞软胶囊治疗脑梗死(CI)患者的临床效果及安全性。方法100例CI患者,采用随机数字表法分为对照组和观察组,每组50例。对照组采用阿托伐他汀钙片治疗,观察组在对照组基础上加用丁苯酞软胶囊治疗。对比两组治疗前后侧支循环[大脑前动脉(ACA)、大脑中动脉(MCA)、大脑后动脉(PCA)]血流速度、Barthel指数量表(BI)评分、缺血区域脑血流量、美国国立卫生研究院卒中量表(NIHSS)评分、血清学指标[同型半胱氨酸(Hcy)、神经元特异性烯醇化酶(NSE)、基质金属蛋白酶-9(MMP-9)]及药品不良反应(ADR)发生情况。结果治疗后,观察组ACA血流速度(42.40±2.37)cm/s、PCA血流速度(27.27±2.41)cm/s低于对照组的(46.88±2.48)、(30.67±2.89)cm/s,MCA血流速度(33.67±2.65)cm/s高于对照组的(22.47±2.70)cm/s,差异具有统计学意义(P<0.05)。治疗后,观察组BI评分(69.45±4.60)分、缺血区域脑血流量(41.04±2.85)ml/(100 g·min)高于对照组的(64.68±4.11)分、(36.52±2.60)ml/(100 g·min),NIHSS评分(8.63±0.89)分低于对照组的(12.87±1.01)分,差异具有统计学意义(P<0.05)。治疗后,观察组Hcy、NSE、MMP-9水平分别为(13.15±1.17)μmol/L、(12.34±1.87)μg/L、(130.54±17.66)μmol/L,低于对照组的(16.55±1.27)μmol/L、(17.54±1.92)μg/L、(162.77±20.45)μmol/L,差异具有统计学意义(P<0.05)。观察组ADR发生率为6.00%,与对照组的4.00%对比差异无统计学意义(P>0.05)。结论对CI患者行阿托伐他汀钙片联合丁苯酞软胶囊治疗,可以改善侧支循环血流速度、神经功能、缺血区域脑血流量、血清学指标,增强患者自理能力,且ADR少,安全性高,值得推广。Objective To evaluate the clinical effect and safety of atorvastatin calcium tablets combined with butylphthalein soft capsules in the treatment of cerebral infarction(CI)patients.Methods A total of 100 CI patients were divided into a control group and an observation group according to the random numerical table,with 50 cases in each group.The control group was treated with atorvastatin calcium tablets,and the observation group was treated with butylphthalein soft capsules on the basis of the control group.Both groups were compared in terms of blood flow velocity of collateral circulation[anterior cerebral artery(ACA),middle cerebral artery(MCA),posterior cerebral artery(PCA)],Barthel index scale(BI)score,cerebral blood flow in ischemic area,National Institutes of Health Stroke Scale(NIHSS)score,serological indicators[homocysteine(Hcy),neuron specific enolase(NSE)and matrix metalloproteinase-9(MMP-9)]before and after treatment,and adverse drug reactions(ADR).Results After treatment,the blood flow velocity of ACA of(42.40±2.37)cm/s and blood flow velocity of PCA of(27.27±2.41)cm/s in the observation group were lower than those of(46.88±2.48)and(30.67±2.89)cm/s in the control group;the blood flow velocity of MCA of(33.67±2.65)cm/s in the observation group was higher than that of(22.47±2.70)cm/s in the control group;the differences were statistically significant(P<0.05).After treatment,BI score of(69.45±4.60)points and cerebral blood flow in ischemic area of(41.04±2.85)ml/(100 g·min)in the observation group were higher than those of(64.68±4.11)and(36.52±2.60)ml/(100 g·min)in the control group;NIHSS score of(8.63±0.89)points in the observation group was lower than that of(12.87±1.01)points in the control group;the differences were statistically significant(P<0.05).After treatment,the levels of Hcy,NSE and MMP-9 in the observation group were(13.15±1.17)μmol/L,(12.34±1.87)μg/L and(130.54±17.66)μmol/L,which were lower than those of(16.55±1.27)μmol/L,(17.54±1.92)μg/L and(162.77±20.45)μmol/L in t

关 键 词：阿托伐他汀钙片 丁苯酞软胶囊 脑梗死 药品不良反应 

分 类 号：R743.33[医药卫生—神经病学与精神病学]